Maryia Zhdanava
Vice President at Analysis Group, Inc.
Data updated
Research Footprint
Maryia Zhdanava appears in 5 tracked papers (2023–2025), most studied alongside Esketamine and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD).
Most-cited paper: Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance (12 citations).
Frequent co-authors: Kruti Joshi, Dominic Pilon and Aditi Shah.
Background & Research
Maryia Zhdanava is a researcher at Analysis Group in Montréal, Canada, and appears as a corresponding author on multiple real-world evidence studies in depression and esketamine. Publicly indexed papers list her as a vice president at Analysis Group, and several publications use the corresponding email format Masha.Zhdanava@analysisgroup.com. Her work focuses on claims-based outcomes, healthcare utilization, costs, and treatment patterns in psychiatric and other therapeutic areas.
Key Impact
She is a health economics and outcomes research author whose real-world studies on esketamine and treatment-resistant depression help characterize access, utilization, costs, and outcomes in psychiatric care.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Maryia Zhdanava is associated with.